{
  "docId": "019de511-116c-769a-af30-00a56112ffbd",
  "docSlug": "6dbbbde9942752c16f9f4678dff28ed3",
  "documentTitle": "Nyxoah | IPO Presentation Deck | 34 slides",
  "authorId": "nyxoah",
  "authorName": "Nyxoah",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2021-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7794254,
  "pageNumber": 25,
  "pageCount": 34,
  "prevPage": 24,
  "nextPage": 26,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de511-116c-769a-af30-00a56112ffbd/25",
  "deckHref": "/decks/019de511-116c-769a-af30-00a56112ffbd",
  "deckJsonHref": "/decks/019de511-116c-769a-af30-00a56112ffbd.json",
  "deckAnchorHref": "/decks/019de511-116c-769a-af30-00a56112ffbd#slide-25",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.5,
        "x": 0.25,
        "y": 0.75
      },
      "kind": "callout",
      "text": "Target commercial availability in the United States in the second half of 2023*",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b22b58ae-a472-409c-8ae5-7119b5145d1e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.5,
        "x": 0.05,
        "y": 0.9
      },
      "kind": "disclaimer",
      "text": "*Assuming positive outcome from the DREAM trial and subsequent FDA marketing authorization",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e0736b10-332a-484d-bead-724c1a5eb478",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "list",
      "text": "Breakthrough device designation process: Allows for additional FDA feedback to sponsors during the pre-marketing phase – sprint sessions with senior FDA management",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4004c9b6-9580-4215-8c5b-58e3d982a92b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.2,
        "x": 0.05,
        "y": 0.4
      },
      "kind": "list",
      "text": "2 regulatory paths: PMA, De Novo",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6b00e16d-f88e-4028-9c46-80209ce0cd51",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.05,
        "y": 0.15
      },
      "kind": "list",
      "text": "Nyxoah received IDE (Investigational Device Exemption) for the DREAM pivotal trial in June 2020",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "83686710-4c23-43aa-b946-9567722abc73",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.6,
        "x": 0.05,
        "y": 0.55
      },
      "kind": "list",
      "text": "Anticipated milestones: Q3 2021: FDA breakthrough device designation dossier submission; Q1 2022: Further discussion with the FDA on regulatory path",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "aa95867b-c7da-4b68-ab50-dbece265ba84",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "US Market Access – FDA Regulatory Strategy",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "86cba9d5-5ffe-4393-9338-4b7090694e2d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "23d37be3-4ac5-4e43-bcaf-86cde39f4162",
      "evidence": "list/bullet: 2 regulatory paths: PMA, De Novo",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}